Konrad Klinghammer

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

Expression of Amphiregulin and EGFRvIII Affect Outcome of Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab–Docetaxel Treatment

Ingeborg Tinhofer, Konrad Klinghammer, Wilko Weichert et al. · Clinical Cancer Research · 2011 · 94 citations · Full text

Medicine, Oncology, Pharmacology +17

Contribution of human papilloma virus to the incidence of squamous cell carcinoma of the head and neck in a European population with high smoking prevalence

Ingeborg Tinhofer, Korinna Jöhrens, Ulrich Keilholz et al. · European Journal of Cancer · 2015 · 85 citations

Medicine, Oncology, Cancer Epidemiology +12

Association of Epidermal Growth Factor Receptor Polymorphism, Skin Toxicity, and Outcome in Patients with Squamous Cell Carcinoma of the Head and Neck Receiving Cetuximab-Docetaxel Treatment

Konrad Klinghammer, Maren Knödler, Alexander Schmittel et al. · Clinical Cancer Research · 2009 · 77 citations

Medicine, Oncology, Pharmacology +16

A comprehensively characterized large panel of head and neck cancer patient‐derived xenografts identifies the m<scp>TOR</scp> inhibitor everolimus as potential new treatment option

Konrad Klinghammer, J.D. Raguse, Thomas Plath et al. · International Journal of Cancer · 2014 · 60 citations

Medicine, Oncology, Pharmacology +17